Signal Genetics Inc Stock Nasdaq
Stocks
US8266401046
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08-31 | Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push | RE |
| 08-07 | Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says | MT |
| Market Cap | 2.61B 2.25B 2.12B 1.93B 3.63B 248B 3.65B 25.03B 9.74B 126B 9.8B 9.58B 418B | P/E 2026 * |
-5.8x | P/E 2027 * | -8.93x |
|---|---|---|---|---|---|
| Enterprise Value | 1.82B 1.57B 1.48B 1.35B 2.53B 173B 2.55B 17.48B 6.8B 87.96B 6.84B 6.69B 292B | EV / Sales 2026 * |
65.3x | EV / Sales 2027 * | 9.1x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Signal Genetics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 30/10/2023 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 12/09/2023 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 03/01/2018 |
Tomas Kiselak
CHM | Chairman | 39 | 01/06/2021 |
Jennifer Moses
BRD | Director/Board Member | 51 | 14/07/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.24% | -1.43% | +2.80% | +16.98% | 49.74B | |
| +2.09% | -0.71% | +452.73% | +498.77% | 44.98B | |
| -1.09% | -0.41% | +35.40% | +15.17% | 42.52B | |
| -0.26% | -4.71% | +17.19% | +71.67% | 40.78B | |
| -0.48% | -0.84% | +16.25% | +49.80% | 32.89B | |
| -1.06% | +2.87% | - | - | 17.09B | |
| -1.81% | -5.02% | +22.65% | +113.24% | 16.28B | |
| -0.11% | -1.84% | +16.42% | +25.80% | 14.4B | |
| -2.05% | -5.14% | +72.89% | +34.69% | 13.48B | |
| Average | -0.73% | -2.44% | +79.54% | +103.26% | 30.24B | |
| Weighted average by Cap. | -0.49% | -2.27% | +97.36% | +122.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.92M 24.09M 22.66M 20.64M 38.82M 2.65B 39.03M 268M 104M 1.35B 105M 103M 4.47B | 232M 200M 188M 171M 322M 21.98B 324M 2.22B 865M 11.18B 869M 851M 37.07B |
| Net income | -466M -402M -378M -344M -648M -44.23B -651M -4.47B -1.74B -22.5B -1.75B -1.71B -74.6B | -322M -278M -261M -238M -448M -30.55B -450M -3.09B -1.2B -15.54B -1.21B -1.18B -51.54B |
| Net Debt | -787M -679M -639M -582M -1.09B -74.7B -1.1B -7.55B -2.94B -38B -2.96B -2.89B -126B | -501M -432M -407M -371M -697M -47.57B -701M -4.81B -1.87B -24.2B -1.88B -1.84B -80.24B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
